Previous 10 | Next 10 |
Crinetics Pharmaceuticals Inc. (CRNX) is expected to report $-0.89 for Q3 2023
Phase 3 PATHFNDR-1 Study Met Primary and All Secondary Endpoints as Reported in September Phase 3 PATHFNDR-2 Study Topline Data Expected in 1Q 2024 Initial Data from Phase 2 Study of Paltusotine in Carcinoid Syndrome Expected in December 2023 SAN DIEGO, Nov. 07, 2023 (GLOB...
2023-10-11 09:00:38 ET FN Media Group Presents USA News Group News Commentary Vancouver, BC – October 11, 2023 – USA News Group – Researchers are becoming increasingly concerned with the rates of cancer on the rise among people under 50. A re...
2023-10-03 07:00:18 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips As economic and stock market uncertainty looms, you may think at first that now is not a great time to be dabbling in speculative stocks. Yet, while the broad market may be experiencing tur...
SAN DIEGO, Sept. 20, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that company management will participate in a fireside chat and 1x1 investor meetings at the Cantor Global Healthcare Conference, which is being held in New York City on September 26-2...
2023-09-19 09:11:54 ET From Sept. 10 to Sept. 15, Crinetics Pharmaceuticals (NASDAQ: CRNX) stock price gained 83%, and it's still climbing rapidly. The pre-revenue biotech's lead candidate, called paltusotine, reported some great phase 3 results, suggesting that the once-daily oral ...
2023-09-18 12:15:50 ET Summary San Diego-based biotech Crinetics Pharmaceuticals saw its share price soar by 75% after positive results from its Phase 3 study of paltusotine, an oral treatment for acromegaly. The study met its primary endpoint and all secondary endpoints, with 83%...
2023-09-15 08:37:48 ET Shares of the rare disease specialist Crinetics Pharmaceuticals (NASDAQ: CRNX) have been on fire this week. Through the first four days of trading, the biotech's stock has already gained a healthy 81.3%, according to data provided by S&P Global Market In...
2023-09-13 06:45:06 ET More on Crinetics Pharmaceuticals Seeking Alpha’s Quant Rating on Crinetics Pharmaceuticals Crinetics Pharmaceuticals: Creating Next-Generation Treatments In Acromegaly Crinetics Pharmaceuticals: Paltusotine Phase 3 Data Presented At END...
SAN DIEGO, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, announced today the pricing ...
News, Short Squeeze, Breakout and More Instantly...
Crinetics Pharmaceuticals Inc. Company Name:
CRNX Stock Symbol:
NASDAQ Market:
Crinetics Pharmaceuticals Inc. Website:
SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will report second quarter 2024 financial results on Thursday, August 8, 2024 after the market closes. Company management will host a conference call at 4:30 p.m. ET that day to...
SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on July 10, 2024, the Compensation Committee of Crinetics’ Board of Directors granted non-qualified stock option awards to purchase an aggregate of 137,900 shares of its com...
2024-06-25 22:36:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...